Xenetic Biosciences (Xenetic Biosciences) Total Liabilities : $0.72 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Xenetic Biosciences Total Liabilities?

Xenetic Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 was $0.72 Mil.

Xenetic Biosciences's quarterly Total Liabilities declined from Sep. 2023 ($1.07 Mil) to Dec. 2023 ($0.81 Mil) and declined from Dec. 2023 ($0.81 Mil) to Mar. 2024 ($0.72 Mil).

Xenetic Biosciences's annual Total Liabilities declined from Dec. 2021 ($1.42 Mil) to Dec. 2022 ($1.07 Mil) and declined from Dec. 2022 ($1.07 Mil) to Dec. 2023 ($0.81 Mil).

Xenetic Biosciences Total Liabilities Historical Data

The historical data trend for Xenetic Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences Total Liabilities Chart

Xenetic Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

4.33

0.96

1.42

1.07

0.81

Xenetic Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															0.86	0.87	1.07	0.81	0.72

Xenetic Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Xenetic Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.81	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.81

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	10.605	-	9.796
	=	0.81

Xenetic Biosciences's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.716	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.72

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	9.394	-	8.678
	=	0.72

Xenetic Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenetic Biosciences (Xenetic Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIOW) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

XBIO:USA

Address

945 Concord Street, Framingham, MA, USA, 01701

Website

https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.